Furthermore, the heme-binding defective mutant, PGRMC1(D120G), reduced the survival of MDA-MB-231 breast cancer cells from doxorubicin and camptothecin [7], implicating the heme-binding capacity of PGRMC1 in regulating susceptibility towards chemotherapeutic agents. This evidence concerns the gene PGRMC1 and breast cancer.